Soliton

Soliton, Inc. was founded in April 2012 as a company developing medical technology devices for medical and aesthetic applications. Soliton's innovative technology platform uses non-invasive rapid high-frequency sound waves to disrupt the structure and connective tissue of target cells, physically impacting the fibrous septa beneath the skin that cause wrinkles. In clinical trial data submitted to the FDA, patients showed significant symptom improvement after a single treatment with RESONIC™, achieving a patient satisfaction rate of 92.9% with subjects agreeing or strongly agreeing.